Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VIS410 in Healthy Volunteers
NCT02045472Phase 1Completed
- Sponsor
- Visterra
- Start
- Sep 2014
- Primary completion
- May 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Influenza A (IAV) comparing VIS410 with Placebo (2 arms). Primary endpoint: Safety assessment. Started Sep 2014; status: completed.
02
Drugs
VIS410
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT02045472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045472.